Weight regain is common after stopping GLP-1 medication. Nutrition and exercise remain important, but they cannot guarantee maintenance or replace the medicine’s effects. Regain can happen despite lifestyle support. 1 2

What withdrawal studies actually show

In the STEP 1 extension, adults without diabetes had received semaglutide 2.4 mg weekly or placebo for 68 weeks. Both medication and structured lifestyle support then stopped. 1

The semaglutide group had lost 17.3% of starting weight on average. One year later, it had regained 11.6 percentage points, roughly two-thirds of that loss, while remaining 5.6% below starting weight. 1

This was an average, not everyone’s outcome. The 327-person extension did not test whether coaching could prevent regain. 1

SURMOUNT-4 provides another important comparison. After initial weight loss with tirzepatide, a dual GIP/GLP-1 medicine, participants either continued treatment or switched to placebo. 2

Those switched to placebo gained 14% of their withdrawal-day weight over 52 weeks, despite continued lifestyle counselling. Continued treatment produced further loss. Neither group included people with diabetes. 2

The practical conclusion: habits matter, but regain is not evidence that someone failed to learn them. 2

Understanding returning appetite

STEP 1 researchers identified the loss of medication-related appetite suppression as a likely contributor to regain, alongside biological responses to weight loss. 1

In a small dietary weight-loss study, lower leptin, higher ghrelin and increased hunger persisted a year later. These hormones help regulate energy balance and appetite. 3

That study did not examine GLP-1 withdrawal. It supports a biological explanation for difficult maintenance, not a prediction that everyone’s hormones or hunger will change identically. 3

Metabolic adaptation: what it does and does not mean

A smaller body generally uses less energy. Metabolic adaptation means an additional reduction in energy expenditure beyond that expected from changes in body size and composition. 4

Its size and persistence vary. In one study of women after dietary weight loss, adaptation measured during weight stability was small and did not predict regain over two years. This was not a GLP-1 study. 4

Lower maintenance needs deserve attention, but a permanently damaged metabolism is not the conclusion. Nor should adaptation be assumed to explain every change on the scales. 4

Why nutrition support during treatment matters

Use treatment to practise eating patterns you can continue, rather than simply trying to eat as little as possible. Priorities include nutrient adequacy, manageable meals and individualised support. 5

  • Include protein foods such as eggs, yoghurt, fish, tofu or beans in meals. 5
  • Keep fruit, vegetables, whole grains and other nutrient-rich foods in the routine. 5
  • Prepare a few repeatable meals and adjust portions with your nutrition professional as appetite changes. 5

For meal-level detail, see nutrition timing on GLP-1 medications.

Body composition trajectory planning

The goal is not just a lower weight. Adequate protein and resistance training support lean-tissue preservation during weight loss. Protein alone is not a substitute for training. 5

Track strength and everyday function alongside weight. See GLP-1 muscle preservation for more detail. 5

BIA estimates body composition; it does not directly measure skeletal muscle or metabolic rate. Hydration changes can affect results, and lean mass is not interchangeable with muscle. 6

If scans are used, compare them under consistent conditions and interpret trends cautiously. A scan cannot confirm that every kilogram lost was fat or prove that regain has been prevented. 6

Planning a medication transition

Discuss stopping with your prescriber before changing doses or injection intervals. Continuing treatment may be appropriate: withdrawal studies support ongoing medication for some people rather than a compulsory exit. 1 2

These trials did not establish that tapering prevents regain. A planned transition means coordinated care, not necessarily a gradual dose reduction. 1 2

Agree a maintenance eating plan rather than automatically increasing calories before stopping. If you have diabetes, ask your prescriber about glucose monitoring and your wider treatment plan. 5

Write down what you will monitor, when follow-up will happen and whom to contact if appetite or weight becomes difficult to manage. 7

The case for ongoing support

NICE recommends regular monitoring and support for at least one year after weight-management treatment ends. This is UK guidance, not an NZ service entitlement or a deadline after which regain risk disappears. 7

Agree practical responses in advance. For example: if work disrupts meal preparation, use your planned backup meals; if weight trends upwards repeatedly, arrange a review rather than waiting for a large regain. 7

Seek help earlier if eating becomes distressing, restriction becomes extreme or weakness develops. These concerns need assessment, not simply tighter portion control. 5

If you would like help turning this into a workable routine, explore our nutrition coaching programmes. Medication decisions remain with your prescriber.